Most Young People Who Die From Sudden Cardiac Arrest Had Warning Signs. We Missed Them.

In April 2025, a Swedish researcher named Matilda Frisk Torell presented findings that should have made front-page news but didn’t. Her team at the University of Gothenburg had spent years combing through the medical histories of every person aged one to thirty-five who died suddenly in Sweden over an entire decade. What they found, published in the American Journal of Cardiology, was both straightforward and damning: among those whose deaths were attributed to sudden arrhythmic death syndrome, the so-called “unexplained” cardiac arrests in structurally normal hearts, 52% had documented symptoms before they died. Syncope. Seizure-like episodes. Abnormal electrocardiograms sitting in medical records. The signals were there. The system didn’t connect the dots.

That statistic reframes the entire conversation around sudden cardiac death in the young. For decades, SADS has been treated as something close to an act of God, an unforeseeable electrical catastrophe in an apparently healthy person’s heart, impossible to predict, impossible to prevent. The Swedish data says otherwise. So does a growing body of research from Denmark, Australia, and the United States that is quietly building the case for a different approach: one that treats these deaths not as bolts from the blue, but as the final failure of a screening and detection system riddled with gaps.

The Numbers Behind the Silence

Sudden cardiac death in people under thirty-five is statistically rare, which is part of why it gets so little systematic attention. A twenty-year nationwide Danish study published in Circulation in 2024 tracked 1,057 sudden cardiac deaths among individuals aged one to thirty-five across 47.5 million person-years of follow-up, arriving at an overall incidence of 2.2 per 100,000 person-years. Two-thirds of victims were male. The median age was twenty-nine. Those numbers are small enough that any individual family physician can practice an entire career without encountering a case, which breeds a dangerous complacency: the problem feels theoretical until a teenager collapses on a basketball court and the community discovers it was always concrete.

The Danish study delivered some encouraging news alongside the grim statistics. Over the two-decade study period, the incidence of witnessed sudden cardiac death declined by 49%, driven largely by improved bystander CPR rates, wider deployment of automated external defibrillators, and a tenfold increase in diagnoses of inherited cardiac conditions. Survival after out-of-hospital cardiac arrest in young people climbed from 3.9% to 28%. But here’s the catch that the optimistic headline obscures: rates of unwitnessed sudden cardiac death didn’t budge. The proportion of deaths that occurred without anyone present to attempt resuscitation actually increased by 79%. We’re getting better at saving the people who collapse in public. We are no better at finding the people who collapse alone, at home, in their sleep.

That asymmetry matters because it points directly at the screening problem. An AED in a gymnasium saves the athlete who arrests during practice. It does nothing for the twenty-three-year-old who dies in bed from an arrhythmia nobody knew was lurking. Prevention, real prevention, requires catching the condition before the first cardiac event, and the Frisk Torell data suggests we’re squandering the opportunities to do exactly that.

What the Swedish Study Actually Found

The SUDDY cohort (SUDden cardiac Death in the Young) is one of the most thorough registries of its kind: every case of sudden cardiac death in individuals aged one to thirty-six in Sweden between 2000 and 2010, verified by autopsy, with five age- and sex-matched population controls per case. Of 903 confirmed sudden cardiac deaths, 149 (roughly 22%) met criteria for SADS, meaning the autopsy showed a structurally normal heart and toxicology was negative. These are the deaths that conventional medicine essentially shrugs at. No blocked artery. No thickened heart muscle. No obvious cause.

Frisk Torell’s team went back into the medical records, national registries, and ECG archives of those 149 SADS victims looking for anything that preceded the fatal event. The findings were striking. Hospitalization for syncope occurred in 4.2% of SADS cases versus 0.41% of controls, a tenfold difference. Seizure-like episodes or convulsions appeared in 3.5% of SADS cases versus 0.14% of controls. Among the subset who’d had an ECG recorded at some point before death, 18% showed pathological abnormalities, with pre-excitation patterns (Wolff-Parkinson-White type findings) being the most common. The victims also showed elevated rates of prior palpitations, nausea, and symptoms associated with infections. Perhaps most provocatively, the study flagged psychiatric disease and psychiatric medication use as potential risk markers warranting further investigation.

The clinical implication is blunt: a young person who faints without clear explanation, or who has an episode that looks like a seizure but doesn’t fit a neat neurological diagnosis, should get a cardiac workup that includes at minimum a resting ECG and, ideally, a referral to a cardiologist familiar with inherited arrhythmia syndromes. That’s not standard practice in most emergency departments. The young man who passes out at a party gets told he was dehydrated. The teenager whose “seizure” produces a normal EEG gets labeled as psychogenic and sent home. These are the missed catches. And the Swedish data quantifies, for the first time in a national cohort, just how often they happen.

The Genetic Architecture of a Stopped Heart

Understanding why SADS happens requires understanding the electrical system of the heart at a molecular level. Every heartbeat depends on the precise, millisecond-timed flow of sodium, potassium, and calcium ions through channels embedded in cardiac muscle cell membranes. These channels are proteins, and the instructions for building them are encoded in genes. When one of those genes carries a pathogenic variant, a mutation that alters the channel’s behavior, the result can be an arrhythmia substrate that lies dormant for years or decades before triggering ventricular fibrillation, the chaotic electrical storm that stops the heart from pumping.

The best-characterized inherited arrhythmia syndromes include long QT syndrome (caused most commonly by variants in KCNQ1, KCNH2, or SCN5A), Brugada syndrome (typically SCN5A), and catecholaminergic polymorphic ventricular tachycardia, or CPVT (usually RYR2 or CASQ2). Long QT syndrome prolongs the heart’s electrical recovery phase, creating a window of vulnerability for a specific type of ventricular arrhythmia called torsades de pointes. Brugada syndrome produces a characteristic ECG pattern (when it’s visible at all, which is intermittent) and predisposes to ventricular fibrillation, often during rest or sleep. CPVT is triggered by exercise or emotional stress, which makes it particularly insidious in young athletes: the very activity that should be keeping them healthy is the one that can kill them. Each of these conditions follows autosomal dominant inheritance, meaning a parent who carries the variant has a 50% chance of passing it to each child.

The diagnostic yield of postmortem genetic testing, the so-called molecular autopsy, has improved substantially with next-generation sequencing. A 2024 study using whole exome sequencing on juvenile sudden cardiac death cases reported identifying probable causative variants in 69% of cases with structurally normal hearts, a dramatic improvement over the roughly 25% yield seen with earlier, more limited gene panels. When postmortem genetic testing is combined with clinical cardiac screening of surviving first-degree relatives, the overall diagnostic yield climbs to approximately 40% even using conservative variant classification under ACMG/AMP guidelines. That number matters because it means we can identify the cause in nearly half of these “unexplained” deaths, and by extension, identify living family members who carry the same risk.

Cascade Screening: Finding the Family Members Who Don’t Know Yet

The concept is elegant and underused. When a young person dies suddenly and genetic testing identifies a pathogenic variant, every first-degree relative (parents, siblings, children) has a 50% probability of carrying the same variant. Cascade genetic screening tests those relatives, and the ones who test positive enter a surveillance and treatment program that can include beta-blockers, activity restrictions, or implantable cardioverter-defibrillators depending on the specific condition. A study of cascade screening in pediatric long QT syndrome families found a screening yield of 39%, with an average of 0.91 new diagnoses per family. Combined genetic and cardiology screening outperformed either approach alone, achieving a 57% yield compared to 29% for genetic-only and 20% for cardiology-only evaluation.

The barriers are human, not technological. Family participation rates hover around 75% when a proband’s genetic testing is positive, but that still leaves one in four families declining or failing to follow through. Some of those refusals stem from fear, denial, or the misguided belief that what they don’t know can’t hurt them. Others come from the fragmented structure of healthcare itself: the medical examiner who orders the autopsy doesn’t talk to the genetic counselor, who doesn’t have a pathway to reach the deceased person’s siblings in another province or state. Updated 2025 guidelines from cardiac genetics consortia recommend limiting routine follow-up to five years for low-risk first-degree adult relatives whose initial evaluations are negative, since the diagnostic yield beyond that window drops below 1%. But getting families into that initial evaluation in the first place remains the bottleneck. Insurance was cited as a barrier in only 6% of cases; the far larger obstacles were families not following through (26%) or actively declining (26%).

The Screening Debate That Shouldn’t Still Be a Debate

Italy mandated ECG screening for all competitive athletes in 1982 and has the longest track record of any country. The reported results are hard to dismiss: the annual incidence of sudden cardiac death among competitive athletes fell from 3.6 per 100,000 in the pre-screening period to 0.4 per 100,000 during the screening years, an 89% decline. Critics have raised methodological questions about those numbers, and an Israeli study found no comparable decline after implementing its own program. The honest answer is that a definitive randomized trial of population-level ECG screening will probably never happen; the event rate is too low and the required sample size too enormous.

What we can say with confidence is that ECG screening catches conditions that history and physical exam alone miss. A meta-analysis published in Clinical Journal of Sport Medicine in 2023 confirmed that ECG combined with history and physical examination detects cardiac disease and conditions related to sudden death at higher rates than history and physical alone. The 2024 Cardiac Safety Research Consortium Think Tank, convened at Duke University and published in the American Heart Journal in 2025, went further: its expert panel concluded that screening limited to athletes with history and physical exam only is “insufficient” and that the current system tolerates a preventable death rate that would be unacceptable in virtually any other context. The report noted that out-of-hospital cardiac arrest in children occurs more than 20,000 times per year in the United States, with survival to hospital discharge around 10%. At schools equipped with an AED, survival exceeds 60%. The gap between those two numbers is a policy failure, not a medical mystery.

Artificial intelligence may be about to change the screening calculus. A deep learning model reported in 2025 achieved cardiologist-level accuracy in identifying the type 1 Brugada pattern on standard twelve-lead ECGs, including patterns subtle enough to escape trained human eyes. If validated at scale, AI-augmented ECG interpretation could turn every routine electrocardiogram into an arrhythmia screening tool: no specialist referral required, no additional testing, just smarter software reading the tracing that’s already being recorded. The technology isn’t speculative; it exists. The question is how quickly it gets deployed into clinical workflows that are notoriously resistant to change.

What a Real Preventive Approach Looks Like

The pieces of an effective screening strategy for sudden cardiac death in the young are sitting on the table, unassembled. A detailed three-generation family history looking for unexplained deaths, syncope, seizures, or drownings under age forty. A resting twelve-lead ECG interpreted by someone trained to recognize the subtle signatures of long QT, Brugada, and pre-excitation syndromes. Exercise stress testing for anyone with exertional symptoms or a family history suggestive of CPVT. Genetic panel testing when clinical evaluation raises suspicion, with cascade screening of relatives when a variant is found. These aren’t experimental interventions. They’re established, guideline-supported evaluations that the vast majority of young people never receive because nobody thought to order them.

The JAMA review by Tseng and Nakasuka published in March 2025 laid out the current state of the evidence with uncomfortable clarity: among young adults who suffer out-of-hospital cardiac arrest, 60% die before reaching the hospital, and only 9 to 16% of total victims survive to discharge. Genetic testing identifies pathogenic variants in 2 to 22% of survivors and 13 to 34% of non-survivors. More than half of victims had identifiable cardiovascular risk factors like hypertension, diabetes, or dyslipidemia. These are not perfectly healthy people struck by unknowable fate. They are inadequately screened people whose risk factors were sitting in plain view, unaddressed, until the moment their hearts stopped.

The conventional healthcare model is structurally unsuited to this problem. A fifteen-minute family medicine appointment doesn’t accommodate a three-generation cardiac history. Provincial fee schedules don’t incentivize the forty-five-minute workup that a young patient with unexplained syncope actually needs. Genetic counseling has multi-month wait times in most Canadian provinces. ECG interpretation in primary care is frequently done by physicians with minimal training in inherited arrhythmia patterns. The Brugada pattern, when present, is missed more often than it’s caught in non-specialist settings. The gap between what the evidence says we should be doing and what the average patient actually receives has nothing to do with knowledge; clinicians know what tests to order. The bottleneck is access and misaligned incentives. Concierge and preventive medicine models exist precisely to close it: to give patients the time, the testing, and the expertise that the standard system consistently fails to deliver when the stakes are highest. This approach directly aligns with recent advancements in preventive cardiology.

Every year, families discover that the person they lost to “unexplained” sudden death had a diagnosable, treatable inherited condition. That discovery often comes too late for the index case, but it doesn’t have to come too late for everyone else in the family. The screening tools exist. The genetic tests exist. The treatments work. What’s missing is the clinical culture and healthcare infrastructure that would put them in front of people before the first arrest, not after. The Swedish data should be the last study we need to prove the point: these deaths leave clues. We just have to start looking for them.

---

References

1. Frisk Torell M, et al. Sudden Arrhythmic Death Syndrome in the Young: Risk Factors are Identifiable Prior to Sudden Cardiac Arrest. American Journal of Cardiology, 2025. DOI: 10.1016/j.amjcard.2025.01.026 www.ajconline.org/article/S0002-9149(25)00626-5/fulltext

2. Jabbari R, et al. Declining Trend of Sudden Cardiac Death in Younger Individuals: A 20-Year Nationwide Study. Circulation, 2024. DOI: 10.1161/CIRCULATIONAHA.124.069431 www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069431

3. Tseng ZH, Nakasuka K. Out-of-Hospital Cardiac Arrest in Apparently Healthy, Young Adults. JAMA, 2025. DOI: 10.1001/jama.2024.26849 jamanetwork.com/journals/jama/article-abstract/2830678

4. Campuzano O, et al. Whole-exome sequencing to identify causative variants in juvenile sudden cardiac death. Human Genomics, 2024. DOI: 10.1186/s40246-024-00657-x link.springer.com/article/10.1186/s40246-024-00657-x

5. Hendrix A, et al. How to: What to expect from genetic testing in SCD management? ESC Council on Cardiovascular Genomics, 2025. ESC Genomics Insight www.escardio.org/Councils/Council-on-Cardiovascular-Genomics/Cardiovascular-Genomics-Insight/Volume-6/how-to-what-to-expect-from-genetic-testing-in-scd-management

6. Burns KM, et al. The 2024 Think Tank on Prevention of Sudden Cardiac Death in the Young: Pathway to Survival. American Heart Journal, 2025. DOI: 10.1016/j.ahj.2025.03.010 www.sciencedirect.com/science/article/pii/S0002870325000924

7. Goff NK, et al. Meta-analysis on the Effectiveness of ECG Screening for Conditions Related to Sudden Cardiac Death in Young Athletes. Clinical Journal of Sport Medicine, 2023. DOI: 10.1177/00099228231152857 journals.sagepub.com/doi/10.1177/00099228231152857

8. Corrado D, et al. Evidence for efficacy of the Italian national pre-participation screening programme. European Heart Journal, 2006. PMID: 16831826 pubmed.ncbi.nlm.nih.gov/16831826/

9. Abdallah H, et al. Artificial intelligence for Brugada syndrome diagnosis and gene variants interpretation. American Journal of Cardiovascular Disease, 2025. PMC11928888 pmc.ncbi.nlm.nih.gov/articles/PMC11928888/

10. Gonzalez Corcia MC, et al. Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic cardiomyopathy. Heart Rhythm, 2019. DOI: 10.1016/j.hrthm.2019.06.013 www.sciencedirect.com/science/article/abs/pii/S1547527119305727

11. Lahrouchi N, et al. Genetic variants associated with sudden cardiac death in the young: a systematic review. Egyptian Journal of Forensic Sciences, 2025. DOI: 10.1186/s41935-025-00450-4 link.springer.com/article/10.1186/s41935-025-00450-4

12. Frisk Torell M, et al. Cohort profile: the Swedish study of SUDden cardiac Death in the Young (SUDDY) 2000–2010. European Journal of Preventive Cardiology, 2022. ResearchGate www.researchgate.net/publication/360526032

Word count: ~2,100